The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Graduate student Giulia Agliardi, from Milan, Italy, studies cancer cells in the Nanomedicine Lab at UCL's School of Pharmacy in London May 2, 2013.
Graduate student Giulia Agliardi, from Milan, Italy, studies cancer cells in the Nanomedicine Lab at UCL's School of Pharmacy in London May 2, 2013.
(Suzanne Plunkett/Reuters)

SCOTT BARLOW

Biotech is back, and no longer bubblicious

ROB Insight is a premium commentary product offering rapid analysis of business and economic news, corporate strategy and policy, published throughout the business day. Visit the ROB Insight homepage for analysis available only to subscribers.

If I told you there is a top-performing equity market sector with mammoth and sustainable profit margins, demographic tail winds, earnings growth well above the market average and which is largely immune from a slowing global economy, you’d suspect that investors had already taken on large positions. But this is not the case. The U.S. biotechnology sector continues to receive minimal attention despite outsized returns and a promising outlook.